Analysts at HC Wainwright cut their FY2024 earnings estimates for shares of Mawson Infrastructure Group in a note issued to investors on Tuesday, November 26th. HC Wainwright analyst K. Dede now ...

Stock analysts at HC Wainwright issued their FY2024 earnings estimates for Immunic in a report issued on Monday, November ...

Fintel reports that on November 25, 2024, HC Wainwright & Co. downgraded their outlook for Mainz Biomed N.V. (NasdaqCM:MYNZ) ...

Fintel reports that on November 26, 2024, HC Wainwright & Co. downgraded their outlook for Cassava Sciences (NasdaqCM:SAVA) ...

Fintel reports that on November 25, 2024, HC Wainwright & Co. initiated coverage of Sarepta Therapeutics (LSE:0L35) with a Sell recommendation. As of November 21, 2024, the average one-year price ...

To access the live webcast of the fireside chat, please visit: https://investor.arbutusbio.com/events-presentations. An archived replay of the webcast will be available on the Arbutus website for a ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

HC Wainwright initiated coverage on Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA), a commercial-stage biopharmaceutical firm primarily focusing on neurological and neuropsychiatry disorders.

HC Wainwright sets an $18 target on Vanda Pharmaceuticals amid a 30% discount to cash reserves. Vanda's portfolio could reach key clinical and regulatory milestones within 6–18 months.

On Wednesday, H.C. Wainwright reaffirmed its Buy rating and $40.00 stock price target for GH Research PLC (NASDAQ:GHRS), following the company's third-quarter financial results and corporate update.

On Tuesday, H.C. Wainwright increased its price target for Bitdeer Technologies Group (NASDAQ: BTDR) to $18.00, up from the previous $17.00, while maintaining a Buy rating on the stock.